Greater than or equal to 1.5 Greater than or equal to 90 100%
1 to 1.49 70 to 89 75%
Less than 1 Less than 70 delay
BC Cancer Agency Protocol Summary BRAJAC Page 1 of 2
Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm 2. Hepatic dysfunction: Dose modification required for DOXOrubicin (see BCCA Cancer Drug Manual). 3. Renal dysfunction: Dose modification may be required for cyclophosphamide (see BCCA Cancer Drug Manual).
PRECAUTIONS: 1. Cardiac Toxicity: DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with severe hypertension or cardiac dysfunction. Cardiac assessment recommended if lifelong dose of 400 mg/m2 to be exceeded (see BCCA Cancer Drug Manual). 2. Extravasation: DOXOrubicin causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines. 3. Neutropenia: Fever or other evidence of infection must be assessed promptly and treated aggressively.
Call Dr. Karen Gelmon or tumour group delegate at (604) 877-6000 or 1-800-663- 3333 with any problems or questions regarding this treatment program.
Date Revised: 1 Feb 2014 (Emetogenicity reclassified)
Reference: Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8(9):1483-96.
BC Cancer Agency Protocol Summary BRAJAC Page 2 of 2
Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm
BC Cancer Protocol Summary For Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Using Carboplatin and Paclitaxel
